Posted by Michael Wonder on 12 May 2018
Decision to fund mercaptopurine oral suspension
10 May 2018 - PHARMAC is pleased to announce the approval of an agreement with Link Pharmaceuticals Limited for the listing of mercaptopurine (Allmercap) oral suspension 20 mg/mL in Section B (Community) and Part II of Section H (DHB Hospital) of the Pharmaceutical Schedule from 1 June 2018.
Funding is subject to Special Authority criteria and DHB Hospital restrictions.
Mercaptopurine oral solution is a suitable formulation for young children who require low doses for the treatment of cancer, mainly acute lymphoblastic leukaemia.
